Weight-loss medications may be poised to reshape psychiatric treatment in unexpected ways. Beyond its established metabolic effects, semaglutide's influence on brain reward circuits suggests therapeutic potential for conditions traditionally managed through behavioral interventions and conventional psychotropic drugs.
This systematic review of 37 studies reveals semaglutide demonstrates efficacy across multiple psychiatric domains. The GLP-1 receptor agonist showed particular promise for binge eating disorder, addressing both weight reduction and cognitive symptoms underlying compulsive eating behaviors. Preliminary evidence suggests benefits for alcohol and substance use disorders, likely through modulation of dopamine pathways that govern addiction. In patients with psychotic disorders, semaglutide helped manage metabolic complications without worsening psychiatric symptoms.
However, the psychiatric profile presents a complex paradox. While some studies document antidepressant-like effects, others report concerning associations with depressive symptoms and suicidal ideation. This contradictory evidence reflects semaglutide's nuanced neurobiological impact—the same mechanisms that reduce food cravings and addictive behaviors may also influence mood regulation in unpredictable ways. The findings align with emerging research on the gut-brain axis and metabolic psychiatry, where compounds targeting metabolic pathways increasingly show psychiatric effects. For clinicians, these results suggest semaglutide requires careful psychiatric monitoring, particularly in vulnerable populations. The therapeutic potential appears genuine but demands rigorous safety protocols. As GLP-1 agonists become more prevalent, understanding their neuropsychiatric effects becomes crucial for both endocrinologists and psychiatrists managing overlapping patient populations.